Emerging Markets Earnings Roundup: Novartis, Eli Lilly (Part 4)
This article was originally published in PharmAsia News
Novartis posted solid growth of 9% in Q1 in emerging markets, with China sales up 21%; Lilly reports strong sales in China lifted revenues by 11%.
You may also be interested in...
The pharma is cutting costs as it continues to reel from revenues lost to generic competition. Meanwhile, it moves its late-stage pipeline forward in hopes of filling the gaps.
Novartis pharma division CFO Harry Kirsch is to replace Jon Symonds as group CFO. The company continues to benefit from the lack of a Diovan monotherapy generic in the U.S., reporting a 2% increase in sales and 7% increase in profits in the first quarter.
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.